We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Breath Test Detects and Diagnoses Stomach Cancer

By LabMedica International staff writers
Posted on 19 Mar 2013
Print article
A simple test that analyzes the chemical signature of a patient's exhaled breath could help diagnose stomach cancer and distinguish it from benign gastric conditions.

The breath test will offer an easier screening tool than endoscopy, where a specially trained medical professional examines the inside of the stomach via a tube inserted down the patient's gullet, and sometimes also retrieves a biopsy sample of the stomach lining.

Scientists at the Technion, the Israel Institute of Technology (Haifa, Israel) used nanomaterial-based sensors to analyze alveolar exhaled breath samples from 130 patients who had undergone endoscopy, and some were biopsied. There were 37 patients who had been diagnosed with stomach cancer, 32 had ulcers, and 61 had less severe stomach complaints. The samples were from patients attending the Anhui Medical University (Hefei, China).

The breath samples were characterized with an array of 14 nanomaterial-based sensors, combined with a statistical pattern recognition algorithm, with the aim of identifying specific patterns, the so-called breath prints for gastric cancer (GC) and nonmalignant gastric conditions, and other subcategories. The sensors included layers of gold nanoparticles with 11 different organic ligands and layers of single-walled carbon nanotubes capped with four different organic overlayers.

The nanomaterial sensors showed an over 90% success rate in distinguishing the patients with stomach cancer from those with more benign complaints. These sensors were more than 90% accurate at distinguishing early from late stage stomach cancers. Chemical analysis found that five volatile organic compounds, 2-propenenitrile, 2-butoxy-ethanol, furfural, 6-methyl-5-hepten-2-one and isoprene were significantly elevated in patients with GC and/or peptic ulcer, as compared with less severe gastric conditions. The encouraging preliminary results from the study have initiated a multicenter clinical trial with considerably increased sample size to confirm the observed breath prints.

The authors suggested that there is a high demand, especially in the developing world, for a simple and noninvasive test for selecting the individuals at increased risk that should undergo the endoscopic examination. Hossam Haick, PhD, a professor at the Technion and senior author of the study said, "The promising findings from this early study suggest that using a breath test to diagnose stomach cancers, as well as more benign complaints, could be a future alternative to endoscopies, which can be costly and time consuming, as well as unpleasant to the patient." The study was published on March 5, 2013, in the British Journal of Cancer.

Related Links:

Technion, the Israel Institute of Technology
Anhui Medical University


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.